CC BY 4.0 · Thromb Haemost
DOI: 10.1055/a-2434-5010
Paola Ranalli
1
Hematology Unit, Pescara Hospital, Pescara, Italy
2
Department of Medicine and Aging Sciences, University of Chieti-Pescara, Chieti, Italy
,
3
Department of Internal Medicine and Thrombosis Expert Center, Maastricht University Medical Centre, and CARIM School for Cardiovascular Diseases, Maastricht, The Netherlands
› Author Affiliations
› Further Information
Also available at
![SFX Search]()
Permissions and Reprints
Publication History
Received: 01 October 2024
Accepted: 02 October 2024
Accepted Manuscript online:
04 October 2024
Article published online:
11 November 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1
Copelan EA,
Chojecki A,
Lazarus HM,
Avalos BR.
Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Rev 2019; 34: 34-44
2
Lin RJ,
Artz AS.
Allogeneic hematopoietic cell transplantation for older patients. Hematology (Am Soc Hematol Educ Program) 2021; 2021 (01) 254-263
3
Sorror ML,
Maris MB,
Storb R.
et al.
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106 (08) 2912-2919
4
Granat LM,
Li H,
Ondeck M.
et al.
Venous thromboembolism post-alogeneic hematopoietic cell transplant: risk factors, incidence and outcomes. Thromb Haemost 2024
5
Zahid MF,
Murad MH,
Litzow MR.
et al.
Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis. Ann Hematol 2016; 95 (09) 1457-1464
6
Young JA,
Pallas CR,
Knovich MA.
Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant 2021; 56 (08) 1805-1817
7
Gerber DE,
Segal JB,
Levy MY,
Kane J,
Jones RJ,
Streiff MB.
The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112 (03) 504-510
8
Annibali O,
Napolitano M,
Avvisati G,
Siragusa S.
Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: critical review of the literature. Crit Rev Oncol Hematol 2018; 124: 41-50
9
Khorana AA,
Francis CW,
Culakova E,
Fisher RI,
Kuderer NM,
Lyman GH.
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24 (03) 484-490
10
Falanga A,
Leader A,
Ambaglio C.
et al.
EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. HemaSphere 2022; 6 (08) e750
11
Ibrahim RB,
Peres E,
Dansey R.
et al.
Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature. Bone Marrow Transplant 2005; 35 (11) 1071-1077
12
Khanal N,
Bociek RG,
Chen B.
et al.
Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia. Am J Hematol 2016; 91 (11) E468-E472
13
Key NS,
Khorana AA,
Kuderer NM.
et al.
Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020; 38 (05) 496-520
14
Khorana AA,
Kuderer NM,
Culakova E,
Lyman GH,
Francis CW.
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
15
Lee A,
Badgley C,
Lo M.
et al.
Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients. Bone Marrow Transplant 2023; 58 (11) 1247-1253
16
Martens KL,
da Costa WL,
Amos CI.
et al.
HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. Blood Adv 2021; 5 (01) 167-175
17
Gangaraju R,
Chen Y,
Hageman L.
et al.
Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model. Blood Adv 2021; 5 (20) 4102-4111
18
Li A,
Martens KL,
Nguyen D.
et al.
External validation of the HIGH-2-LOW model: a predictive score for venous thromboembolism after allogeneic transplant. Am J Hematol 2022; 97 (06) 740-748
19
Nevo S,
Enger C,
Swan V.
et al.
Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. Transplantation 1999; 67 (05) 681-689
20
El Jurdi N,
Elhusseini H,
Beckman J.
et al.
High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. Blood Cancer J 2021; 11 (05) 96
21
Agnelli G,
Becattini C,
Meyer G.
et al;
Caravaggio Investigators.
Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
22
McBane II RD,
Wysokinski WE,
Le-Rademacher JG.
et al.
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (02) 411-421
23
Noumegni SR,
Mansourati V,
Tromeur C.
et al.
Risk factors of cardiovascular death after venous thromboembolism: results from a prospective cohort study. Thromb Haemost 2022; 122 (10) 1744-1756
24
Danilatou V,
Dimopoulos D,
Kostoulas T,
Douketis J.
Machine learning-based predictive models for patients with venous thromboembolism: a systematic review. Thromb Haemost 2024; 124 (11) 1040-1052
25
Gorog DA,
Gue YX,
Chao TF.
et al.
Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022; 122 (10) 1625-1652
26
Olie RH,
Winckers K,
Rocca B,
Ten Cate H.
Oral anticoagulants beyond warfarin. Annu Rev Pharmacol Toxicol 2024; 64: 551-575
留言 (0)